Sign In

Lung Cancer

Tarlatamab: A New Therapy Approved for Small-Cell Lung Cancer

Investigational ROS1 Inhibitor Zidesamtinib For NSCLC: What to Know

Osimertinib Plus Chemotherapy Improves Overall Survival in EGFR-Mutant NSCLC: New Findings from Dana-Farber Clinical Trial

Kavontae Smalls

Immunotherapy For Small Cell Lung Cancer: Groundbreaking New Developments Offer Hope To Patients

Kavontae Smalls

Imfinzi Improves Overall & Progression-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer

Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval

Osimertinib (Tagrisso) Leads To More Tumor Shrinkage For EGFR+ Lung Cancer Patients: Unpacking The New Data

Kavontae Smalls

Immunotherapy Drug Imfinzi Plus Chemotherapy Boosts Survival Rates In Metastatic Lung Cancer Patients: New Study

Latest Outcomes from the PACIFIC Trial Suggest Overall Survival Improvement for Lung Cancer

Study Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care

Decision Making Between Second- and Third-Generation ALK Inhibitors for Lung Cancer

Could Durvalumab (Imfinzi) Improve Survival in Early-Stage NSCLC?

Unprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients

‘Great Urgency’ to Understand KRAS as an Actionable Marker in Lung Cancer

Dr. Balazs Halmos,

UCLA Medical Center

Lung Cancer — The Nuances of Mutations & Targeted Therapies

Tarlatamab for Small Cell Lung Cancer — Talking To Patients About The Risks & Benefits

Dr. David Gasalberti

Patient Care Updates

Importance of Monitoring Lung Cancer Patients on Imfinzi for Possible Pneumonitis

Osimertinib: A New Standard of Care for Stage III EGFR-Mutated Non-Small Cell Lung Cancer

Biomarker Testing in Lung Cancer - It Must Be Standard Of Care

Predicting Which Lung Cancer Patients Will Benefit From Immunotherapy

Targeted Therapies Offer Greater Precision in Advanced Lung Cancer Treatment

Metastatic Lung Cancer – Deciding on Next Steps

Immunotherapy for Lung Cancer - It's Not for Everyone

Enhertu Approval: New Opportunities for Antibody-Drug Conjugates in Lung Cancer Therapy

MHQ: Clinical IntelligencePowered by SurvivorNet

Health Panel
Clinical Trials

?

Prefer to talk instead of typing?

Answers offered are informational and do not constitute medical advice. Learn more

Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

Clinical Trials

Clear List